Novartis in the midst of hundreds of NJ layoffs. This spring and summer, Novartis is laying off 427 employees who report to East Hanover, after it let go of 235 staff members at the Morris County ...

Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities. The move comes after President Trump earlier this week threatened "major" tariffs on pharmaceuticals.

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, a move that would save the company $1 billion over the next two years. Additionally, the company spun off its generics ...

Novartis has also been examining Lutathera for other indications. In September, it released Phase 2 data on Lutathera improving progression-free survival in patients with meningioma brain tumors. The ...

The probe began in September 2022, with Novartis issuing a release acknowledging that it had been targeted by COMCO and the EC.. Six weeks later, the company revealed in a financial report that ...

Novartis American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidance.

Novartis paid an undisclosed upfront fee to form the original PDC pact. Now, the Swiss drugmaker has put down a further $180 million and offered up to $2.71 billion in milestones to expand the ...

Novartis on Tuesday expanded its peptide discovery collaboration with Japanese biotech PeptiDream in a deal worth more than $2.7 billion in milestone payments, making it the latest move in the red hot ...

Novartis is committing $100 million to Voyager Therapeutics to see if the biotech’s technology can lead to new gene therapies for Huntington’s disease and spinal muscular atrophy.. According ...

Novartis’ remibrutinib could be a game-changer for patients with chronic spontaneous urticaria. Estimates suggest the new drug could eventually top $1 billion in peak annual sales for Novartis ...

Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge ...

Figure 1: Total return 2017-2022: Novartis vs SP 500 vs S&P Health Firms. Steve Denning; Seeking Alpha 1. The Starting Place For Novartis. The mission of Novartis is admirably simple and customer ...